Oppenheimer analyst Jay Olson maintains $Enanta Pharmaceuticals (ENTA.US)$ with a hold rating, and adjusts the target price from $16 to $14.
According to TipRanks data, the analyst has a success rate of 37.6% and a total average return of 10.8% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Enanta Pharmaceuticals (ENTA.US)$'s main analysts recently are as follows:
Enanta reported Q4 results highlighting quarterly HCV royalties of $14.6M, operating expenses of $44.5M, and cash reserves of $248.2M, anticipated to sustain operations into 2027. The company is poised to announce topline results from its Phase 2 RSVPEDs study of zelicapavir in infants and children with RSV in December.
The firm noted that the Q4 report was straightforward and emphasized the critical nature of the upcoming RSVPEDs readout in December, which is expected to be a key determinant of zelicapavir's future potential in RSV.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
